Key facts
- It has raised $165.0M; the latest was Later Stage VC ($100.0M) in Feb 2026.
- Notable investors include HSG (Hong Kong), ZhenFund, CDH Investments, SIG (China), Trustar Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Deep Intelligent Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Deep Intelligent Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deep Intelligent Pharma
Developer of artificial intelligence-based drug discovery and pharmaceutical research software designed to support data-driven decision-making in life science. The company applies deep learning and natural language processing to extract, normalize, and analyze biomedical and pharmaceutical data from diverse structured and unstructured sources, enabling pharmaceutical companies, biotechnology firms, and research institutions to reduce manual information processing, prioritize R&D opportunities, and improve the efficiency and consistency of discovery and development activities.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2017
- Employees
- 100
- Website
- dip-ai.com/
- Ownership
- Privately Held (backing)
Deep Intelligent Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deep Intelligent Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deep Intelligent Pharma in its N-PORT filings yet. We sweep new filings monthly.